Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Avoiding Pitfalls in the Statistical Analysis of Heterogeneous Tumors.

Axelrod DE, Miller N, Chapman JA.

Biomed Inform Insights. 2009 Jan 1;2:11-18.

2.

National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009.

Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, Pike MC, Reed SD, Saftlas AF, Scarvalone SA, Schwartz AM, Slomski C, Yothers G, Zon R.

J Natl Cancer Inst. 2010 Feb 3;102(3):161-9. doi: 10.1093/jnci/djp485. Epub 2010 Jan 13.

3.

Tumor heterogeneity: causes and consequences.

Marusyk A, Polyak K.

Biochim Biophys Acta. 2010 Jan;1805(1):105-17. doi: 10.1016/j.bbcan.2009.11.002. Epub 2009 Nov 18. Review.

4.

Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast.

Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Weaver DL, Winer E; Members of the Cancer Committee, College of American Pathologists.

Arch Pathol Lab Med. 2009 Jan;133(1):15-25. doi: 10.1043/1543-2165-133.1.15. No abstract available.

PMID:
19123730
5.

Effect of quantitative nuclear image features on recurrence of Ductal Carcinoma In Situ (DCIS) of the breast.

Axelrod DE, Miller NA, Lickley HL, Qian J, Christens-Barry WA, Yuan Y, Fu Y, Chapman JA.

Cancer Inform. 2008;6:99-109. Epub 2008 Mar 1.

6.

Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.

Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, O'Connell P, Tsimelzon A, Medina D.

Clin Cancer Res. 2008 Jan 15;14(2):370-8. doi: 10.1158/1078-0432.CCR-07-1127.

7.

Ductal carcinoma in situ of the breast (DCIS) with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment.

Chapman JA, Miller NA, Lickley HL, Qian J, Christens-Barry WA, Fu Y, Yuan Y, Axelrod DE.

BMC Cancer. 2007 Sep 10;7:174.

8.

Heterogeneity of ductal carcinoma in situ and its effects on management.

Mokbel K, Cutuli B.

Lancet Oncol. 2006 Sep;7(9):756-65. Review.

PMID:
16945771
9.

Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.

Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, Fehm T, Solomayer E, Riess O, Wallwiener D, Kurek R, Neubauer HJ.

Cancer Res. 2006 May 15;66(10):5278-86.

10.

Karyometry of infiltrating breast lesions.

Frank DH, Davis JR, Ranger-Moore J, Liu Y, Bartels HG, Alberts DS, Bartels PH.

Anal Quant Cytol Histol. 2005 Aug;27(4):195-201.

PMID:
16220830
11.

Patterns of chromosomal alterations in breast ductal carcinoma in situ.

Hwang ES, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Thor A, Ljung BM, Waldman FM.

Clin Cancer Res. 2004 Aug 1;10(15):5160-7.

12.

Ductal carcinoma in situ, complexities and challenges.

Leonard GD, Swain SM.

J Natl Cancer Inst. 2004 Jun 16;96(12):906-20. Review.

13.

Ductal carcinoma in situ of the breast.

Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM.

N Engl J Med. 2004 Apr 1;350(14):1430-41. Review. No abstract available.

PMID:
15070793
14.

Optimal management of ductal carcinoma in situ of the breast.

Sakorafas GH, Farley DR.

Surg Oncol. 2003 Dec;12(4):221-40. Review.

PMID:
14998563
15.

Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy.

Kerlikowske K, Molinaro A, Cha I, Ljung BM, Ernster VL, Stewart K, Chew K, Moore DH 2nd, Waldman F.

J Natl Cancer Inst. 2003 Nov 19;95(22):1692-702.

16.

Gene expression profiles of human breast cancer progression.

Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, Chatfield E, Kessler J, Baer TM, Erlander MG, Sgroi DC.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9. Epub 2003 Apr 24.

17.

Molecular markers in ductal carcinoma in situ of the breast.

Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, Richardson A, Cooper A, Strausberg R, Riggins GJ, Schnitt S, Gabrielson E, Gelman R, Polyak K.

Mol Cancer Res. 2003 Mar;1(5):362-75.

18.

Proteomics of human breast ductal carcinoma in situ.

Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin EF 3rd, Zhao Y, Steeg PS.

Cancer Res. 2002 Nov 15;62(22):6740-9.

19.

Histologic classification of ductal carcinoma in situ.

Jaffer S, Bleiweiss IJ.

Microsc Res Tech. 2002 Oct 15;59(2):92-101. Review.

PMID:
12373719
20.

Standard for the management of ductal carcinoma in situ of the breast (DCIS).

Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Harris Ja, O'Malley F, Schnitt SJ, Singletary SE, Winchester DP; American College of Surgeons; College of American Pathology; Society of Surgical Oncology; American College of Radiology.

CA Cancer J Clin. 2002 Sep-Oct;52(5):256-76. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk